Notably, the experimental mouse IL‐6R antibodies (1F7 and 25F10) used in our current study block IL‐6 trans‐signaling in the mouse, and have previously been reported to ameliorate tumorigenesis in the KrasG12D LAC model, albeit not as effectively as the robust anti‐tumor activity observed here with A17pro (Brooks et al, 2016). This evidence concerns the gene IL6 and neoplasm.